Efficacy of Dapagliflozin Combined with Lifestyle Intervention in Obesity Control

Abstract

Objective. To explore the best treatment of obesity in middle and old age. Methods. 80 obese patients in our hospital from January 2020 to December 2021 were randomly divided into the control group and the intervention group according to the numerical table method. The control group was treated with lifestyle intervention, while the intervention group was treated with dapagliflozin combined with lifestyle intervention. The effects of body weight, body mass index (BMI), waist circumference, and blood lipids (LDL, HDL, TC, and TG) were measured and compared. Anxiety and depression scores were assessed using the 2018 Revised Anxiety and Depression Scale. Results. There were no significant differences in body weight, BMI, and waist circumference between the control group and the intervention group before treatment. After treatment, the weight, BMI, and waist circumference of the intervention group were lower than those of the control group, and the difference was statistically significant ( P < 0.05 ). After treatment, LDL, TC, and TG in the two groups were decreased, and HDL was significantly increased ( P < 0.05 ). After treatment, the blood lipid level in the intervention group was significantly lower than that in the control group ( P < 0.05 ). Anxiety and depression symptoms improved in both groups, and there were no serious adverse effects. Conclusion. Dapagliflozin in combination with a lifestyle intervention effectively and safely treats excess weight in middle-aged and older adults, reverses obesity-related markers, and improves psychological symptoms. Its curative effect is better than that of using lifestyle intervention alone.

Sodium-Glucose Cotransporter-2 Inhibitors in Depression

“…There was no significant difference in Becks Anxiety Inventory (BAI) changes, but subjects had low anxiety at baseline (BAI < 10 at baseline in all treatment arms). A second RCT by Dai and colleagues, 102 primarily studying weight loss with SGLT2 inhibitor dapagliflozin, included the 2018 Revised Anxiety and Depression Scale as a secondary end point. While the authors reported improvements in depression in both arms of the study, all patients in the intervention arm who met enrollment criteria for depression no longer met full criteria at the end point.…”

Retracted: Efficacy of Dapagliflozin Combined with Lifestyle Intervention in Obesity Control

“…This article has been retracted by Hindawi, as publisher, following an investigation undertaken by the publisher [ 1 ]. This investigation has uncovered evidence of systematic manipulation of the publication and peer-review process.…”